NCT03648489 - Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Ovarian CancerOvarian NeoplasmsOvarian CarcinosarcomaOvarian Serous AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Clear Cell AdenocarcinomaFallopian Tube CancerFallopian Tube NeoplasmsPrimary Peritoneal CarcinomaPrimary Peritoneal Serous Adenocarcinoma

Interventions

DRUG

Paclitaxel

Please refer to arm/group description

DRUG

TAK228

Please refer to arm/group description

Trial Locations (15)

Unknown

Charité Universitätsmedizin Berlin, Berlin

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

KEM Kliniken Essen-Mitte, Essen

Churchill Hospital, Oxford

Weston Park Hospital, Sheffield

Southampton General Hospital, Southampton

LA14 4LF

Furness General Hospital, Barrow in Furness

SW17 0QT

St George's University Hospitals NHS Foundation Trust, London

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

W12 0HS

Imperial College Healthcare NHS Trust, London

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

M20 4BX

The Christie NHS Foundation Trust, Manchester

LA1 4RP

Royal Lancaster Infirmary, Lancaster

HA6 2RN

Mount Vernon Cancer Centre, Northwood

NG5 1PB

Nottingham University Hospitals NHS Trust, Nottingham

All Listed Sponsors

collaborator

Takeda Pharmaceuticals International, Inc.

INDUSTRY

collaborator

North Eastern German Society of Gynaecological Oncology

OTHER

lead

Imperial College London

OTHER